tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

AMAM

Ambrx Biopharma’s Landmark Merger and Corporate Overhaul
Company AnnouncementsAmbrx Biopharma’s Landmark Merger and Corporate Overhaul
7M ago
8K
AMAM
Ambrx Biopharma: Vote Results and Forward-Looking Statements Warning
PremiumCompany Announcements
Ambrx Biopharma: Vote Results and Forward-Looking Statements Warning
7M ago
8K
AMAM
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
PremiumPress Releases
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
7M ago
AMAM
Ambrx Biopharma shareholders approve acquisition by Johnson & Johnson
PremiumThe Fly
Ambrx Biopharma shareholders approve acquisition by Johnson & Johnson
7M ago
JNJ
AMAM
Ambrx Biopharma Nears Acquisition by Johnson & Johnson
PremiumCompany Announcements
Ambrx Biopharma Nears Acquisition by Johnson & Johnson
7M ago
8K
AMAM
Ambrx Biopharma downgraded to Neutral from Outperform at Baird
PremiumThe FlyAmbrx Biopharma downgraded to Neutral from Outperform at Baird
8M ago
AMAM
Ambrx Biopharma downgraded to Market Perform from Outperform at JMP Securities
Premium
The Fly
Ambrx Biopharma downgraded to Market Perform from Outperform at JMP Securities
8M ago
JNJ
AMAM
Ambrx Biopharma downgraded to Neutral from Buy at B. Riley
Premium
The Fly
Ambrx Biopharma downgraded to Neutral from Buy at B. Riley
8M ago
AMAM
Ambrx Biopharma downgraded to Neutral from Buy at BTIG
PremiumThe Fly
Ambrx Biopharma downgraded to Neutral from Buy at BTIG
9M ago
AMAM
M & A News: Johnson & Johnson (NYSE:JNJ) to Acquire Ambrx Biopharma
PremiumMarket News
M & A News: Johnson & Johnson (NYSE:JNJ) to Acquire Ambrx Biopharma
9M ago
JNJ
AMAM
Ambrx Biopharma downgraded to Sector Perform from Outperform at RBC Capital
PremiumThe Fly
Ambrx Biopharma downgraded to Sector Perform from Outperform at RBC Capital
9M ago
AMAM
Ambrx Announces Sale to Johnson & Johnson
PremiumPress Releases
Ambrx Announces Sale to Johnson & Johnson
9M ago
AMAM
Johnson & Johnson to acquire Ambrx Biopharma for $2B in cash
PremiumThe FlyJohnson & Johnson to acquire Ambrx Biopharma for $2B in cash
9M ago
JNJ
AMAM
Ambrx Biopharma to be acquired by Johnson & Johnson for $28.00 per share
Premium
The Fly
Ambrx Biopharma to be acquired by Johnson & Johnson for $28.00 per share
9M ago
JNJ
AMAM
Ambrx Biopharma to be added to the Nasdaq Biotechnology Index
Premium
The Fly
Ambrx Biopharma to be added to the Nasdaq Biotechnology Index
9M ago
AMAM
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
PremiumPress Releases
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
9M ago
AMAM
Ambrx Biopharma provides update on APEX-01
PremiumThe Fly
Ambrx Biopharma provides update on APEX-01
10M ago
AMAM
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
PremiumPress Releases
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
10M ago
AMAM
Cantor biotech/biopharma analysts hold analyst/industry conference call
PremiumThe Fly
Cantor biotech/biopharma analysts hold analyst/industry conference call
10M ago
JNJ
LLY
Ambrx Biopharma price target lowered to $22 from $26 at Baird
PremiumThe FlyAmbrx Biopharma price target lowered to $22 from $26 at Baird
10M ago
AMAM
Cantor biotech/biopharma analysts hold analyst/industry conference call
Premium
The Fly
Cantor biotech/biopharma analysts hold analyst/industry conference call
10M ago
JNJ
LLY
Ambrx Biopharma options imply 9.7% move in share price post-earnings
Premium
The Fly
Ambrx Biopharma options imply 9.7% move in share price post-earnings
10M ago
AMAM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >